Organisation paid for research Program year 2024 Source: CMS Open Payments

Wellspan Oncology Research

Neither a doctor nor a teaching hospital

Research payments

$192,207

9 payments

Through program year 2024, Wellspan Oncology Research is reported as receiving $192,207 in research payments, across 9 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2024	Research	$2,004	1
2023	Research	$2,228	1
2020	Research	$187,975	7

Breakdown

Who paid Research payments · program years 2020–2024

Array BioPharma Inc. $187,975 7 payments
E.R. Squibb & Sons, L.L.C. $4,232 2 payments

Studies the money was for Research payments · program years 2020–2024

A Phase 2 Openlabel Study of Encorafenib Binimetinib in Patients With Brafv600emutant Nonsmall Cell Lung Cancer $187,975 7 payments
Phase III #1 RRMM: (MM-003) 480Vd vs PVd (Capped Scenario, 29 mo enr, 38.8 mo to PE) SUCCESSOR 1 - A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, $2,228 1 payment
Phase III 1L DLBCL CC-99282+RCHOP vs RCHOP - A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Prev $2,004 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.